Hearing in humans is managed by a specialised organ called the cochlea. The cochlea contains specialised sensory cells that detect sound and transmit this to the brain. Rinri is developing the world’s first regenerative cell therapies capable of repairing damaged sensory cells in the cochlea.

Rinri’s first product, Rincell-1, is designed to regenerate the auditory nerves in the inner ears of patients with hearing loss caused by damage to these cells.

Our research clearly demonstrates that Rincell-1 can survive, engraft, mature and re-establish neural connections to auditory hair cells and wider auditory neural architecture. In models of auditory neuron-related hearing loss, these cells result in a reversal of hearing loss and a 40% improvement in the hearing threshold.

For information regarding ongoing clinical trials, and evaluating our drug candidates, please refer to Be Part of Research (nihr.ac.uk) and follow up with your healthcare provider. You may search by disease, location of clinical trials, or by the name of the company sponsoring the clinical trials. Additionally, you can find information on clinical trials on the RNID website.

You may also email clinicaltrials@rinri-therapeutics.com

Rinri is currently focused on developing Rincell-1 and its application in the UK.

To stay informed on the status of our clinical studies, please reference our latest press releases and the Investors & Media section of our website.

Rincell-1 is being developed to restore hearing in patients with acquired sensorineural hearing loss, specifically auditory neuron-related hearing loss. As trials progress, it may have further applications.